Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumithra J Mandrekar

Showing results (11-20 of 157) with videos related to

Pageof 16
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2011
All-comers versus enrichment design strategy in phase II trialsSumithra J Mandrekar, Daniel J Sargent
Clinical Investigation|March 6, 2012
Design of clinical trials for biomarker research in oncologySumithra J Mandrekar, Daniel J Sargent
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2009
Biostatistics: a toolkit for exploration, validation, and interpretation of clinical dataJayawant N Mandrekar, Sumithra J Mandrekar
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Pick the winner designs in phase II cancer clinical trialsSumithra J Mandrekar, Daniel J Sargent
Journal of Biopharmaceutical Statistics|April 23, 2009
Clinical trial designs for predictive biomarker validation: one size does not fit allSumithra J Mandrekar, Daniel J Sargent
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 6, 2008
Case-control study design: what, when, and why?Jayawant N Mandrekar, Sumithra J Mandrekar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challengesSumithra J Mandrekar, Daniel J Sargent
NEJM Evidence|February 6, 2024
Strategies to Account for Design Misspecifications in Randomized Controlled TrialsAmy S Ruppert, Sumithra J Mandrekar
Current Problems in Cancer|November 25, 2006
Combining symptom and survival dataPamela J Atherton, Sumithra J Mandrekar
Clinical Trials (London, England)|April 16, 2010
Predictive biomarker validation in practice: lessons from real trialsSumithra J Mandrekar, Daniel J Sargent
Pageof 16

Showing results (11-20 of 157) with videos related to

Sort By:
Pageof 16
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2011
All-comers versus enrichment design strategy in phase II trialsSumithra J Mandrekar, Daniel J Sargent
Clinical Investigation|March 6, 2012
Design of clinical trials for biomarker research in oncologySumithra J Mandrekar, Daniel J Sargent
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2009
Biostatistics: a toolkit for exploration, validation, and interpretation of clinical dataJayawant N Mandrekar, Sumithra J Mandrekar
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Pick the winner designs in phase II cancer clinical trialsSumithra J Mandrekar, Daniel J Sargent
Journal of Biopharmaceutical Statistics|April 23, 2009
Clinical trial designs for predictive biomarker validation: one size does not fit allSumithra J Mandrekar, Daniel J Sargent
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 6, 2008
Case-control study design: what, when, and why?Jayawant N Mandrekar, Sumithra J Mandrekar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challengesSumithra J Mandrekar, Daniel J Sargent
NEJM Evidence|February 6, 2024
Strategies to Account for Design Misspecifications in Randomized Controlled TrialsAmy S Ruppert, Sumithra J Mandrekar
Current Problems in Cancer|November 25, 2006
Combining symptom and survival dataPamela J Atherton, Sumithra J Mandrekar
Clinical Trials (London, England)|April 16, 2010
Predictive biomarker validation in practice: lessons from real trialsSumithra J Mandrekar, Daniel J Sargent
Pageof 16